In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21% vs 8%, respectively – chi-square p = 0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p = 0.0063).
Keskmine progressioonivaba elulemus oli vastavalt 2, 89 ja 1, 88 kuud (logaritmiline astak- p = 0, 0063).